Back to all studies
Not recruitingISRCTN11177045

A Phase II Double-blinded study of Intravenous Immunoglobulins and Rituximab in people with Antibody-associated Psychosis (SINAPPS2)

This study is not recruiting in the United Kingdom. It focuses on Antibody-associated psychosis; Mental and Behavioural Disorders.

Schizophrenia, Mental healthOtherFrom 16 Years to 70 Years

The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.

Then choose your country and confirm availability with each study site.

In plain English

Key information made simple

What is this study testing?

This study is testing whether Intravenous Immunoglobulins and Rituximab may be useful for people experiencing schizophrenia.

What would participation involve?

Participants may receive Intravenous Immunoglobulins and Rituximab, complete questionnaires or follow-up assessments, attend study visits with the research team. The protocol may also involve randomization, placebo, or a comparison group. The registry lists locations in the United Kingdom.

Who is it mainly for?

This study appears to be mainly for people with schizophrenia.

What should you check before joining?

Ask about the dose, safety monitoring, and possible side effects, whether there is placebo, randomization, or a comparison group, how many visits or travel steps are needed, the exact eligibility criteria.

Your next step

Check the study details

Check the official source, then confirm these points with the research team.

View official study record (opens in a new tab)
  • Recruitment and eligibility

    Is a site open, and who can take part?

  • Visits and time

    Where are visits, can any be remote, and how much time is needed?

  • Costs and support

    What costs, reimbursement or compensation apply?

Before joining

Questions to ask before joining

Study clarity

Things to check before joining

Study start dateStarted: November 1, 2017
Recruitment status
Not recruiting
Enrollment listed in the registry
Not clearly listed
Sponsor
Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge
Sponsor type
University
Study type
Other
Intervention type
Other / unclear
Study phase
Not clearly listed
Locations
United Kingdom
Age range
From 16 Years to 70 Years
Official registry ID
ISRCTN11177045
Official title
A Randomised Phase II Double-blinded Placebo-controlled Trial of Intravenous Immunoglobulins and Rituximab in Patients With Antibody-associated Psychosis (SINAPPS2)

Ask HopeStage to help me review this study

This record does not confirm open recruitment. We can help you understand it and explore other studies.

Loading the security check...
Study ID: ISRCTN11177045. We help you review the study, but cannot decide medical eligibility.

Check recruitment and locations

Recruitment checked against the registry by HopeStage on . Registry information can change. Always confirm availability with the research team.

View official study record (opens in a new tab)

The overall study status can differ from each site's status. Open a country to see its locations and their registry status.

United Kingdom · 10 sites
  • Cambridge University Hospitals NH Foundation Trust
    Cambridge
    Site status: Not listed — confirm with the team
  • Royal Devon and Exeter NHS Foundation Trust
    Exeter
    Site status: Not listed — confirm with the team
  • NHS Greater Glasgow and Clyde
    Glasgow
    Site status: Not listed — confirm with the team
  • The Walton Centre NHS Foundation Trust
    Liverpool
    Site status: Not listed — confirm with the team
  • University College London Hospitals Nhs Foundation Trust
    London
    Site status: Not listed — confirm with the team
  • King's College Hospital NHS Foundation Trust
    London
    Site status: Not listed — confirm with the team
  • Salford Royal NHS Foundation Trust
    Manchester
    Site status: Not listed — confirm with the team
  • Nottingham University Hospitals NHS Trust
    Nottingham
    Site status: Not listed — confirm with the team
  • Oxford University Hospitals NHS Foundation Trust
    Oxford
    Site status: Not listed — confirm with the team
  • Sheffield Teaching Hospitals NHS Foundation Trust
    Sheffield
    Site status: Not listed — confirm with the team
In practice

For you

Participation may contribute to research. Personal benefit is not guaranteed.

Ask the research team to explain the activities, time commitment, and follow-up involved.

Study sites are listed. Confirm the relevant site and any travel before making plans.

Important

Not medical advice

Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com

FAQ

Questions about this study

What is this study trying to understand?

This study is exploring digital app or tool for people with schizophrenia. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed. The detailed objective is not always clearly listed in the public registry; the study team can confirm.

Why is the study type not clearly categorized?

The study type is not clearly categorized in the public registry. Focus on the objective, required tasks, visits, any intervention, and eligibility criteria, then ask the study team to confirm.

Who might this study be for?

This study may concern people with schizophrenia; age range: From 16 Years to 70 Years. The criteria appear fairly broad, but you should not assume you are eligible. The study team must confirm diagnosis, age, exclusions, available locations, and next steps.

What would I likely need to do?

The public registry does not clearly describe all participation steps. The listed study locations suggest that at least part of participation may involve a physical site. Ask whether some steps can be done remotely.

What risks or points should I check?

The public registry does not make the main risk category clear. Ask the study team what activities are required, what could feel uncomfortable, how safety is monitored, and what happens if you want to stop. For any mental health study, also ask who to contact if you feel worse, whether participation may affect current treatment, whether you can stop, and who confirms eligibility.

Will I need to travel or attend in-person visits?

The listed study locations suggest that at least part of participation may involve a physical site. Ask which sites are open, how many visits are expected, whether any steps can be done remotely, and whether travel costs or compensation are listed.

Who is behind this study?

This study is sponsored by Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge, which appears to be a university. If available, it can be useful to check the sponsor website, collaborators, investigator affiliation, and the official registry before deciding. HopeStage does not judge the quality of a sponsor or researcher, but helps you identify what to verify.

Can I still join this study?

The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.

Explore other studies

Want to find a study that may fit you better?

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.

Find a study that may fit me